Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01594216
Title Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

estrogen-receptor positive breast cancer

Therapies

Exemestane + Ruxolitinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.